Physician profile
Travis Peck
NPI 1982132502
$12,287.50
in general payments reported to CMS, 2019-2025
17 companies · $8,026 in 2025
The $8,026 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $248 · 2021: $1,099 · 2022: $853 · 2023: $1,109 · 2024: $829 · 2025: $8,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,516 · Food and Beverage: $3,105 · Travel and Lodging: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,516.00 |
| Food and Beverage | $3,105.34 |
| Travel and Lodging | $341.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $7,057.22 | 2025 | Eylea Hd |
| Alcon Vision LLC | $1,548.41 | 2020-2023 | Ngenuity, Constellation |
| Genentech USA, INC. | $761.32 | 2022-2025 | Vabysmo |
| Abbvie INC. | $628.42 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $566.37 | 2024-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $367.59 | 2023-2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $237.93 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $205.78 | 2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $174.97 | 2019-2020 | |
| Genentech, INC. | $150.31 | 2022 | |
| Allergan, INC. | $139.05 | 2021 | |
| Glaukos Corporation | $122.80 | 2021 | |
| Bausch & Lomb Americas INC. | $103.74 | 2023 | Stellaris |
| Eyepoint US, INC. | $95.76 | 2023 | |
| Astellas Pharma US INC | $59.98 | 2024-2025 | Izervay |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $44.04 | 2025 | Izervay |
| Harrow Eye, LLC | $23.81 | 2025 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.